Thymosin Alpha-1
Also known as: Ta1, Thymalfasin, Zadaxin
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
Thymosin alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in the 1970s. The synthetic version (thymalfasin, marketed as Zadaxin) has been approved in over 35 countries (though not the US or EU) for hepatitis B and C treatment and as an immune adjuvant. It is one of the most extensively studied immune-modulating peptides, with over 4,400 published studies. It enhances both innate and adaptive immune responses.
Plain Language Summary
Thymosin alpha-1 is a peptide naturally produced by your thymus gland, which is important for immune function. A synthetic version called Zadaxin is approved in many countries around the world (but not the US) for treating hepatitis B and boosting the immune system. It is one of the most well-studied peptides available, with thousands of published research papers. Some people use it for general immune support and longevity purposes.
Mechanism of Action
Thymosin alpha-1 acts as an immune modulator by: activating toll-like receptors (TLR2, TLR9) on dendritic cells, promoting dendritic cell maturation and antigen presentation, enhancing T-cell differentiation and function (particularly CD4+ and CD8+ T cells), stimulating natural killer (NK) cell activity, promoting Th1 over Th2 immune responses, and modulating inflammatory cytokine production. It also enhances antibody responses to vaccines. Its immunomodulatory (rather than purely immunostimulatory) profile means it can both boost weak immune responses and dampen excessive inflammation.
Evidence Summary
Extensive clinical data exist, primarily from trials in hepatitis B (where it improved viral clearance rates and HBeAg seroconversion), hepatitis C (improved sustained virological response when combined with interferon), cancer immunotherapy adjunct (improved response rates in hepatocellular carcinoma, melanoma, and NSCLC when combined with standard therapy), and sepsis (reduced mortality in severe sepsis in several trials). A meta-analysis of sepsis trials showed significant mortality reduction. It has also been used as a vaccine adjuvant in immunocompromised patients. Evidence quality varies; some trials are well-designed RCTs, while others are smaller or open-label.
Safety Profile
Thymosin alpha-1 has an excellent safety profile documented across thousands of patients in clinical trials and post-marketing use. The most common adverse event is injection site discomfort. No significant systemic toxicity has been reported even at high doses. The immunomodulatory (vs. immunostimulatory) mechanism means it has not been associated with autoimmune flares or cytokine storms. It is generally considered one of the safest peptides in clinical use.
Contraindications
- Known hypersensitivity
- Organ transplant recipients on immunosuppression (theoretical risk of rejection)
- Pregnancy (insufficient data, though animal studies showed no teratogenicity)
Adverse Events
- Injection site discomfort (mild)
- Rarely: muscle aches
- Rarely: fatigue
- Overall very well tolerated
Interactions
- May enhance vaccine responses (beneficial interaction)
- Theoretical concern with immunosuppressants (may counteract their effects)
- Has been safely combined with interferons, chemotherapy, and antivirals in clinical trials
Regulatory Notes
Thymalfasin (Zadaxin) is approved in over 35 countries (including China, Russia, India, multiple countries in Asia, South America, and Eastern Europe) for hepatitis B, hepatitis C, and as an immunotherapy adjuvant. It is NOT approved by the FDA or EMA. SciClone Pharmaceuticals was the primary developer. The regulatory landscape varies significantly by jurisdiction. In the US, it is available as a compounded peptide or research chemical.
Monitoring Considerations
Immune function markers (lymphocyte subsets, NK cell activity) may be monitored in clinical settings. Standard liver function tests if used for hepatitis. Monitor vaccine titers if used as a vaccine adjuvant. Generally, monitoring requirements are minimal given the safety profile.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Lyophilized thymosin alpha-1 is stable when stored at 2-8C. The Zadaxin formulation has well-characterized stability. Grey-market and compounded versions vary in quality. Reconstituted solutions should be used promptly.
References
- 1meta-analysis
Thymosin Alpha 1 Therapy for Sepsis: A Meta-Analysis
Li C, Bo L, Liu Q, et al. (2015). International Journal of Infectious Diseases
Key findings: Meta-analysis of 12 RCTs showed thymosin alpha-1 significantly reduced mortality in severe sepsis (RR 0.59, 95% CI 0.45-0.77).
Limitations: Heterogeneity in study populations and protocols. Most trials from China.
- 2RCT
Thymalfasin (Thymosin-Alpha 1) for Treatment of Hepatitis B: Results of a Phase 3 Trial
Chan HL, Tang JL, Tam W, et al. (2001). Antimicrobial Agents and Chemotherapy
Key findings: Thymosin alpha-1 improved HBeAg seroconversion and virological response in chronic hepatitis B compared to placebo.
Limitations: Moderate sample size. Endpoint definitions varied between studies.
- 3review
Thymosin Alpha 1: A Comprehensive Review of the Literature
Tuthill C, Rios I, McBeath R. (2010). Expert Opinion on Biological Therapy
Key findings: Comprehensive review covering 4,400+ publications. Summarizes clinical use in hepatitis, cancer immunotherapy, and immune restoration.
Limitations: Review article. Authors affiliated with SciClone Pharmaceuticals.
Last reviewed: 2024-12-05 | Version: 1 | Status: Published
More in Longevity/Immune
Epitalon
Epithalon · Epithalone · AGAG · Ala-Glu-Asp-Gly
Epitalon is a small lab-made peptide based on a substance from the pineal gland, studied primarily by Russian researchers for anti-aging purposes. The claim is that it can activate telomerase, an enzyme that helps maintain the protective caps (telomeres) on your chromosomes, potentially slowing aging. The evidence for these claims is very limited, and it is not approved anywhere as a medication. It is one of the more speculative peptides available in the grey market.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c
MOTS-c is a naturally occurring peptide produced by your mitochondria (the energy factories in your cells). It acts like an exercise signal, helping your body use sugar more efficiently and improving insulin sensitivity. Levels of MOTS-c naturally decrease as you age. A small human study showed that daily injections improved how the body handles insulin in obese men. It is still very early in research and is only available through grey-market sources.
Humanin
HN · HNG (S14G-humanin) · [Gly14]-Humanin
Humanin is a naturally occurring peptide made by your mitochondria that protects cells from dying. It was discovered through Alzheimer disease research, where it was found to prevent brain cell death. Studies in animals suggest it could protect the heart, brain, and metabolic systems. Humanin levels naturally drop as you age. While promising in laboratory studies, it has not been tested in human clinical trials and remains a research-only compound.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider